The FDA has fully approved Selzentry tablets (maraviroc, from Pfizer) for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. Previously, Selzentry was granted accelerated conditional approval in August 2007. The full approval is based on the 48-week MOTIVATE study, where patients treated with Selzentry plus optimized background therapy showed significantly higher increases in CD4 cells and greater log reductions in viral load. Also, more than twice as many Selzentry plus optimized background therapy patients were able to achieve undetectable viral loads when compared to placebo plus optimized background therapy patients.
For more information call (800) 438-1985 or visit www.selzentry.com.